Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nuvaxovid
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Nuvaxovid (NVX-CoV2705) is a recombinant protein nanoparticle vaccine developed by Novavax in partnership with Sanofi, specifically engineered to target the SARS-CoV-2 Omicron JN.1 variant. The vaccine consists of 5 mcg of purified recombinant spike protein and is formulated with 50 mcg of the Matrix-M adjuvant, a saponin-based component that enhances the immune response by stimulating antigen-presenting cells. Unlike mRNA-based COVID-19 vaccines, Nuvaxovid uses a traditional protein subunit platform. Sanofi leads the commercialization and regulatory efforts for this formulation, which received FDA Emergency Use Authorization in August 2024 and full Biologics License Application (BLA) approval in May 2025 for use in individuals aged 12 years and older.
- Brand names
- Nuvaxovid
- Other names
- Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula)Omicron JN.1 SARS-CoV-2 rS VaccineNovavax COVID-19 Vaccine (JN.1 formulation)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Nuvaxovid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuvaxovid.